Krystal Biotech (KRYS) Retained Earnings (2016 - 2026)

Krystal Biotech has disclosed Retained Earnings across 11 years of filings, most recently posting $80.1 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at $80.1 million, up 155.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.1 million (up 155.28% YoY), and the FY2025 annual result was $1.1 million, up 697.89% from the prior year.
• Retained Earnings came in at $80.1 million for Q1 2026 at Krystal Biotech, up from $1.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $80.1 million in Q1 2026 to a low of -$268.9 million in Q1 2024.
• The 5-year median for Retained Earnings is -$382000.0 (2023), against an average of -$71.9 million.
• Across the five-year window, Retained Earnings sank 174510.39% in 2024 and surged 697.89% in 2025, its largest moves.
• Krystal Biotech's Retained Earnings stood at -$728000.0 in 2022, then soared by 187.64% to $638000.0 in 2023, then plunged by 129.78% to -$190000.0 in 2024, then soared by 697.89% to $1.1 million in 2025, then jumped by 6951.06% to $80.1 million in 2026.
• The last three Retained Earnings figures came in at $80.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.